Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 06 2021
15 06 2021
Historique:
received:
19
10
2020
revised:
23
12
2020
accepted:
09
04
2021
pubmed:
17
4
2021
medline:
8
4
2022
entrez:
16
4
2021
Statut:
ppublish
Résumé
Prognostic uncertainty is a major challenge for cancer of unknown primary (CUP). Current models limit a meaningful patient-provider dialogue. We aimed to establish a nomogram for predicting overall survival (OS) in CUP based on robust clinicopathologic prognostic factors. We evaluated 521 patients with CUP at MD Anderson Cancer Center (MDACC; Houston, TX; 2012-2016). Baseline variables were analyzed using Cox regression and nomogram developed using significant predictors. Predictive accuracy and discriminatory performance were assessed by calibration curves, concordance probability estimate (CPE ± SE), and concordance statistic (C-index). The model was subjected to bootstrapping and multi-institutional external validations using two independent CUP cohorts: V1 [MDACC (2017), Baseline characteristics of entire cohort ( Our user-friendly CUP nomogram integrating commonly available baseline factors provides robust personalized prognostication which can aid clinical decision making and selection/stratification for clinical trials.
Identifiants
pubmed: 33858857
pii: 1078-0432.CCR-20-4117
doi: 10.1158/1078-0432.CCR-20-4117
pmc: PMC8197749
mid: NIHMS1695624
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3414-3421Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
J Clin Oncol. 2002 Dec 15;20(24):4679-83
pubmed: 12488413
Br J Cancer. 2015 Mar 17;112(6):1088-97
pubmed: 25688736
Am J Hosp Palliat Care. 2008 Apr-May;25(2):139-45
pubmed: 18445863
Br J Cancer. 2014 Jan 7;110(1):208-13
pubmed: 24169348
J Clin Oncol. 2004 May 1;22(9):1721-30
pubmed: 15117995
Palliat Med. 2008 Mar;22(2):177-83
pubmed: 18372382
JAMA. 1999 Dec 22-29;282(24):2333-9
pubmed: 10612321
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32188704
J Clin Oncol. 2011 Jan 1;29(1):61-8
pubmed: 21098322
Cancer Treat Rev. 2013 Nov;39(7):701-8
pubmed: 23566573
JAMA Oncol. 2015 Apr;1(1):40-49
pubmed: 26182302
Int J Clin Oncol. 2014;19(3):479-84
pubmed: 23813044
J Clin Oncol. 2018 Jun 20;36(18):1861-1867
pubmed: 29683788
BMC Cancer. 2019 Oct 17;19(1):965
pubmed: 31623602
J Clin Oncol. 2011 Jun 10;29(17):2319-26
pubmed: 21555700
J Clin Oncol. 2016 Oct 20;34(30):3605-3608
pubmed: 27551112
JAMA. 1998 Jun 3;279(21):1709-14
pubmed: 9624023
Sci Rep. 2019 Dec 23;9(1):19673
pubmed: 31873162
J Clin Oncol. 2019 Mar 1;37(7):570-579
pubmed: 30653423
Bioethics. 2003 Apr;17(2):142-68
pubmed: 12812182
J Clin Oncol. 2015 Nov 10;33(32):3809-16
pubmed: 26438121
Cancer. 2006 Dec 1;107(11):2698-705
pubmed: 17063500
J Palliat Med. 2014 Jun;17(6):673-82
pubmed: 24742212
J Clin Oncol. 2008 Mar 10;26(8):1364-70
pubmed: 18323559
JAMA. 2014 Nov 12;312(18):1888-96
pubmed: 25387186
Int J Cancer. 2020 Jun 1;146(11):3053-3064
pubmed: 31970771
J Palliat Med. 2018 Mar;21(3):315-321
pubmed: 28920751
BMJ. 2004 Jun 5;328(7452):1343
pubmed: 15151964
Stat Med. 1990 Nov;9(11):1303-25
pubmed: 2277880
Ann Oncol. 2017 Dec 1;28(12):3015-3021
pubmed: 29045506
Semin Oncol. 2009 Feb;36(1):60-4
pubmed: 19179189
Intern Med J. 2017 Apr;47(4):408-414
pubmed: 28101916
BMJ Open. 2017 Sep 27;7(9):e017881
pubmed: 28963312
BMJ Support Palliat Care. 2015 Dec;5(4):366-72
pubmed: 24644189
JAMA. 2008 Oct 8;300(14):1665-73
pubmed: 18840840
J Clin Oncol. 2011 Feb 20;29(6):755-60
pubmed: 21263086